Status:
UNKNOWN
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
Ferring Pharmaceuticals
Conditions:
Diminished Ovarian Reserve
Eligibility:
FEMALE
18-40 years
Brief Summary
The study aims to explore the genetic pathogenesis of diminished ovarian reserve via whole-genome sequencing technology in Chinese women.
Detailed Description
Diminished ovarian reserve (DOR), a pathological condition of reduced quantity and quality of oocytes, has severe impairment on women fertility. Some women experience DOR may develop into premature ov...
Eligibility Criteria
Inclusion
- DOR group:
- age between 18 and 40 years;
- number of oocytes obtained in previous ovarian stimulation cycles ≤3;
- bilateral ovarian antral follicle count (AFC) \< 5-7;
- serum anti-Mullerian hormone (AMH) \<0.5-1.1ng/ml.
- Control group:
- age between 18 and 40 years;
- bilateral AFC ≥8;
- serum AMH ≥1.2ng/ml;
- regular menstrual cycles occurring every 25-35 days.
Exclusion
- The exclusion criteria of the two groups were:
- an abnormal karyotype;
- a history of other endocrine diseases such as polycystic ovary syndrome, hyperprolactinemia and hyperthyroidism;
- a history of radiotherapy, chemotherapy and ovarian surgery.
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT04711772
Start Date
September 1 2020
End Date
December 31 2022
Last Update
January 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 510515